These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 11998553)

  • 1. Health needs, drug registration and control in less developed countries--the Peruvian case.
    Figueras A; Vasquez S; Arnau JM; Laporte JR
    Pharmacoepidemiol Drug Saf; 2002; 11(1):63-4. PubMed ID: 11998553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiepileptic drugs in children in developing countries: research and treatment guideline needs.
    Farkhondeh M; Hill SR; Cross JH; Dua T
    Epilepsia; 2009 Nov; 50(11):2340-3. PubMed ID: 19744112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cuban experience in focusing pharmaceuticals policy to health population needs: initial results of the National Pharmacoepidemiology Network (1996-2001).
    Diogène E; Pérez PJ; Figueras A; Furones JA; Debesa F; Laporte JR;
    Pharmacoepidemiol Drug Saf; 2003; 12(5):405-7. PubMed ID: 12899116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Building community partnerships: case studies of Community Advisory Boards at research sites in Peru, Zimbabwe, and Thailand.
    Morin SF; Morfit S; Maiorana A; Aramrattana A; Goicochea P; Mutsambi JM; Robbins JL; Richards TA
    Clin Trials; 2008; 5(2):147-56. PubMed ID: 18375653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Epilepsies: industrialized countries versus developing countries].
    Genton P
    Soins; 2007 Nov; (720):25-7. PubMed ID: 18376739
    [No Abstract]   [Full Text] [Related]  

  • 7. The Global TB Drug Facility: innovative global procurement.
    Kumaresan J; Smith I; Arnold V; Evans P
    Int J Tuberc Lung Dis; 2004 Jan; 8(1):130-8. PubMed ID: 14974756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in consumption of psychiatric drugs in Serbia and Montenegro 2000-2004.
    Divac N; Tosevski DL; Babić D; Djurić D; Prostran M; Samardzić R
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):835-8. PubMed ID: 16958148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Essential medicines for the whole world.
    Reidenberg MM
    Clin Pharmacol Ther; 2007 Nov; 82(5):500-3. PubMed ID: 17952105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adapting developing country epidemiological assessment techniques to improve the quality of health needs assessments in developed countries.
    Smith SM; Long J; Deady J; O'Keeffe F; Handy D; O'Dowd T
    BMC Health Serv Res; 2005 Apr; 5():32. PubMed ID: 15862122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The potential demand for family planning: new data on unmet needs and estimates for five Latin American countries].
    Westoff CF
    Perspect Int Planif Fam; 1988; (Special):2-11. PubMed ID: 12281824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs for neglected diseases: from pipeline to patients.
    Pécoul B
    PLoS Med; 2004 Oct; 1(1):e6. PubMed ID: 15526054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis.
    Garrison LP; Towse A; Bresnahan BW
    Health Aff (Millwood); 2007; 26(3):684-95. PubMed ID: 17485745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The review of drug applications submitted to the European Medicines Evaluation Agency: frequently raised objections, and outcome.
    Pignatti F; Aronsson B; Gate N; Vamvakas S; Wade G; Moulon I; Le Courtois P
    Eur J Clin Pharmacol; 2002 Dec; 58(9):573-80. PubMed ID: 12525957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applying genomics-related technologies for Africa's health needs.
    Singer PA; Court EB; Bhatt A; Frew SE; Greenwood H; Persad DL; Salamanca-Buentello F; Séguin B; Taylor AD; Daer HT; Daar AS
    Afr J Med Med Sci; 2007; 36 Suppl():7-14. PubMed ID: 17703557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards a healthy use of pharmaceuticals.
    Laporte JR
    Dev Dialogue; 1985; (2):48-55. PubMed ID: 12341047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matching needs and services: an assessment tool for community-based service systems.
    Melamid E; Brodbar G
    Child Welfare; 2003; 82(4):397-412. PubMed ID: 12875369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.